FY2024 Earnings Forecast for JAZZ Issued By Leerink Partnrs

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the specialty pharmaceutical company will post earnings per share of $16.57 for the year, up from their prior forecast of $16.47. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.95 per share.

Other equities analysts also recently issued research reports about the stock. TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Piper Sandler reiterated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Trading Up 0.6 %

Jazz Pharmaceuticals stock opened at $125.05 on Thursday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $7.56 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The stock has a 50-day moving average of $122.74 and a two-hundred day moving average of $115.83. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,253 shares of company stock worth $890,594 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wedge Capital Management L L P NC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $32,497,000. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Cinctive Capital Management LP purchased a new position in Jazz Pharmaceuticals during the third quarter worth approximately $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Jazz Pharmaceuticals by 47.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock valued at $29,945,000 after buying an additional 86,768 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.